Skip to main content
OpenTrials
Completed

NCT Number: NCT01119716

International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)

This study will create a prospective registry of consecutive patients with Atrial Fibrillation (Afib) considered for cardioversion treatment to document up-to-date practice of in-hospital treatment, with a focus on the characterization of type of Afib, as well as on treatments applied (drugs, devices, interventions and their combinations), and associated complications within 60 days after enrollment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant with documented atrial fibrillation (confirmed by electrocardiogram) in the hospital setting at the time of enrollment
  • Planned cardioversion (of atrial fibrillation)

Exclusion criteria

  • Already enrolled in this or any other clinical trial
  • Atrial flutter

Treatment and study plan

Primary outcomes

  1. Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission)

    Time frame: Baseline (time of admission)

  2. Co-Morbidity in Participants Presenting With Atrial Fibrillation at Baseline (Admission)

    Time frame: Baseline (time of admission)

  3. Clinical Type of Atrial Fibrillation at Baseline (Admission)

    Time frame: Baseline (time of admission)

  4. Treatments Utilized for Participants for Atrial Fibrillation

    Time frame: At time of Treatment (up to 1 day from admission)

  5. Percentage of Participants Who Had a Successful Electrical or Pharmacological Cardioversion

    Time frame: At time of treatment (up to 1 day from admission)

    Pharmacological cardioversion was considered successful if sinus rhythm or atrial rhythm was obtained within 24 hours after its initiation. Electrical cardioversion was considered successful if sinus rhythm was obtained and maintained for at least 10 minutes after the last shock was administered.

  6. Complications Experienced by Participants Who Underwent a Cardioversion for Treatment of Atrial Fibrillation

    Time frame: up to 60 days from day of treatment (cardioversion)

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Collaborators

  • Institut für Herzinfarktforschung an der Universität Heidelberg

Registry information

Official study title

International Registry on Cardioversion of Atrial Fibrillation

Acronym: RHYTHM-AF

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
May 7, 2010
Registry last updated
Jun 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.